[Effects of PTEN gene on invasion and migration of ovarian cancer cell line A2780 and related mechanisms].
Department of Gynecological Oncology, Tianjin Medial University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China. Zhonghua zhong liu za zhi [Chinese journal of oncology]
03/2011; 33(3):165-8. DOI: 10.3760/cma.j.issn.0253-3766.2011.03.003
To evaluate the effects of PTEN on invasive and migration ability of human ovarian cancer cell line A2780 and related mechanisms.
The plasmid including WT-PTEN and mutant PTEN were transferred into A2780 cells. The invasive and migration ability were measured before and after transfection by transwell chamber and wound-healing assays. The expression of PTEN protein and related proteins in the cells were detected by Western blot analysis. Empty plasmid-transfected A2780 and normal A2780 cells were used as control (the different four groups were named as WT-PTEN/A2780, C124A-PTEN/A2780, GFP/A2780 and A2780).
The number of penetrating cells was significantly less in WT-PTEN/A2780 cells (24.3 ± 2.5) than those in C124A-PTEN/A2780, GFP/A2780 and A2780 cells (43.7 ± 3.8, 44.7 ± 2.1 and 45.0 ± 3.0) (P < 0.05). The migration distance was markedly shorter in WT-PTEN/A2780 cells (54.1 ± 3.7) than those in C124A-PTEN/A2780, GFP/A2780 and A2780 cells (78.7 ± 3.4, 78.1 ± 3.1 and 76.8 ± 3.5) (P < 0. 05).
Transfection with PTEN may suppress the invasive and migration ability of ovarian cancer cell line A2780 depending on its phosphatase activity, and the suppressive effect may be due to the down-regulation of MMP-9 in the cancer cells.
Available from: Pravir Kumar
[Show abstract] [Hide abstract]
ABSTRACT: The ongoing Cancer Genome Project (CGP) aims at sequencing the genes with the mutations which cause cancer. In this review, we aim to simplify the information
given in the COSMIC (Catalogue of somatic mutation in cancer). PTEN (Phosphatase and tensin homolog) is a tumor suppressor gene and is involved in many
cellular functions. The mutation in PTEN has been seen in many cancers and especially it is seen in high incidence in endometrial cancer, central nervous system
cancer, prostate cancer etc. The analysis is based on the data given in the COSMIC database. PTEN mutation, although has been found in cancers but in CGP drug
sensitivity project, no drug has been till date targeted. This may be due to lack of enough research on PTEN or proper data analysis has not been done. Thus this
review gives an insight of how PTEN can also be a potential drug target. In this review mutations have been grouped in different type of cancers, which makes it
easier to infer data and statistics. This in turn gives an easy and comprehensive reference to the data which can be used for future research.
[Show abstract] [Hide abstract]
ABSTRACT: The relevance of potentially reversible post-translational modifications required for controlling cellular processes in cancer is one of the most thriving arenas of cellular and molecular biology. Any alteration in the balanced equilibrium between kinases and phosphatases may result in development and progression of various diseases, including different types of cancer, though phosphatases are relatively under-studied. Loss of phosphatases such as PTEN (phosphatase and tensin homologue deleted on chromosome 10), a known tumour suppressor, across tumour types lends credence to the development of phosphatidylinositol 3--kinase inhibitors alongside the use of phosphatase expression as a biomarker, though phase 3 trial data are lacking. In this review, we give an updated report on phosphatase dysregulation linked to organ-specific malignancies.Oncogene advance online publication, 18 March 2013; doi:10.1038/onc.2013.80.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.